Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2001

View Archived Issues

Phase II trial to compare two ciprofloxacin formulations for urinary tract infections

FDA accepts for review Picovir NDA for use in the common cold

AtheroGenics begins phase I trial of AGIX-4207 for rheumatoid arthritis

ICN acquires promising liver-targeting hepatitis B compound

FDA approves Dermagraft living human dermal substitute

Chromax dietary supplement undergoes clinical testing for treatment of depression

Marine sponge-derived compound with antiinflammatory properties

Sch-351125: an orally bioavailable anti-HIV CCR5 antagonist

Human monoclonal antibody targeting IL-15 advances to clinical trials in RA patients

Molsidomine reduces upregulated prostacyclin synthase mRNA in hypoxic pulmonary hypertension

Antinociceptive effects demonstrated for the synthetic cannabinoid HU-210

Pharmacological profile of PTK-787/ZK-222584, a new, orally active angiogenesis inhibitor

Divalproex as a treatment strategy for alcohol withdrawal syndrome

Progenics licenses drug in clinical development for reducing peripheral opioid side effects

NIH supports development of inhaled gene therapy for hemophilia B

Topiglan well tolerated by both males and their female partners during intercourse

GSK develops highly potent and selective COX-2 inhibitors

VEGF receptor tyrosine kinase inhibitors and their use in cancer

New oxazolidinone antibacterial agents with broad-spectrum activity

Aventis patents new series of bone resorption inhibitors

P&G compounds reportedly useful for treating and preventing ischemia-reperfusion injury

AstraZeneca team discovers inhibitors of iNOS useful for inflammation and pain

Inhibitors of beta-amyloid aggregation claimed by JT for use in dementia

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...